Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Post-market Clinical Follow-up Study on the Performance and Safety of a Vent Catheter Used During Cardiopulmonary Bypass.

1 juni 2026 bijgewerkt door: Bıçakcılar Tıbbi Cihazlar Sanayi ve Ticaret A.Ş.

Prior to the implementation of the Medical Device Regulation (MDR), the clinical evaluation of existing devices was conducted by Notified Bodies (NBs) based on clinical data obtained from equivalent devices, and CE certificates were issued for devices exhibiting similar characteristics. Following the transition to the MDR, the European Commission's Guidance Document MEDDEV 2.12/2 highlighted that Notified Bodies, which issued CE certificates under the previous regime, must now organize Post-Marketing Clinical Follow-up (PMCF) studies to verify the performance and safety of the device in accordance with its intended use throughout its lifecycle. Consequently, PMCF studies are being planned to demonstrate that medical devices previously marked with the CE mark under the old regulations are used safely for patients throughout their lifecycle.

Primary Objective To demonstrate the performance of the Bıçakcılar Vent Catheter in patients for whom its use is planned, in accordance with the device's intended purpose as outlined in the user manual, taking into account the following aspects: bleeding, trauma, passage manipulation, insertion and removal, compliance with the intended use, occlusion, retention of debris, effective use, and maintenance of its form

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Primary Endpoints The primary endpoints have been designed to encompass all clinical outcomes that characterize the device's performance. The evaluation items listed below, which are directly related to the Bıçakcılar Vent Catheter, will be measured using a Likert scale with values ranging from 1 to 5.

  • Presence of bleeding
  • Impact of trauma
  • Manipulation during insertion
  • Placement
  • Removal (including removal of the stylet, if applicable)
  • Conformity to intended use/Drainage capability
  • Blockage formation in the ports
  • Presence of residue
  • Effective use
  • Retention of shape

Secondary Endpoints Since factors such as the surgeon performing the operation, the perfusionist operating the heart-lung machine, and the patients' clinical characteristics may act as confounding variables, other variables affecting the primary endpoints will be identified through secondary endpoints.

  • General and demographic information
  • Concomitant diseases
  • Concomitant treatments
  • Biochemical findings
  • Echocardiographic findings
  • Total duration of the procedure
  • Type of procedure
  • Vital and cardiac assessments
  • Evaluations related to the Vent catheter
  • Perfusion evaluations
  • Cardioplegia evaluations
  • Data on adverse events and complications

Definition of Participants (Volunteers) / Study Population Patients for whom a decision has been made by their physician to undergo routine surgical procedures using cardiopulmonary bypass, and for whom the use of a vent catheter is planned during the procedure

Studietype

Observationeel

Inschrijving (Geschat)

45

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

  • Patients with diseased or abnormal tissue at the catheter insertion site
  • Patients with intracardiac and/or major intravascular thrombi and/or masses
  • Patients with left atrial/ventricular myxoma
  • Patients who have difficulty understanding or complying with the study
  • Patients who may present a conflict of interest (e.g., relatives of employees of the sponsoring company)
  • Patients who have participated in any clinical trial within the past 30 days

Beschrijving

Inclusion Criteria:

  • Patients who have consulted the Department of Cardiovascular Surgery and for whom the physician has decided to perform heart surgery using the cardiopulmonary bypass technique,

    • Patients for whom the use of a vent catheter is planned during surgery
    • Patients who, in the "Use of Patient Data for Educational and Research Purposes" section of the Department of Cardiovascular Surgery Informed Consent Form, have given permission for their data to be used

Exclusion Criteria:

  • • Patients with diseased or abnormal tissue in the catheter placement site

    • Patients with intracardiac and/or major intravascular thrombi and/or masses
    • Patients with left atrial/ventricular myxoma
    • Patients who have difficulty understanding or complying with the study
    • Patients who may pose a conflict of interest (e.g., relatives of employees of the sponsoring company)
    • Patients who have participated in any clinical trial within the past 30 days

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Trauma effects
Tijdsspanne: It will be measured during the surgery up to 6 hours.
Primary endpoints are structured to encompass all clinical use outcomes characterizing device performance. Evaluation items directly related to the Bıçakcılar Vent Catheter will be measured using a Likert scale with values ranging from 1 to 5.
It will be measured during the surgery up to 6 hours.
Presence of bleeding
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used the 5-likert scale.
It will be measured during the surgery up to 6 hours.
Manipulation during insertion
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used 5-likert scale.
It will be measured during the surgery up to 6 hours.
Catheter placement
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used the 5-likert scale.
It will be measured during the surgery up to 6 hours.
Catheter removal
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used the 5-likert scale.
It will be measured during the surgery up to 6 hours.
Removal of the stylet (If the catheter contains a stylet)
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used the 5-likert scale.
It will be measured during the surgery up to 6 hours.
Suitability of the device for its intended use / emptying capability
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used 5-likert scale.
It will be measured during the surgery up to 6 hours.
Blockage in the holes during emptying
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used 5-likert scale.
It will be measured during the surgery up to 6 hours.
Was there any residue left on the catheter surface after the removal procedure was completed?
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used 5-likert scale.
It will be measured during the surgery up to 6 hours.
Was its use as a filler for air extraction effective?
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used 5-likert scale.
It will be measured during the surgery up to 6 hours.
Has the device retained its pre-operation form? (Evaluate for deformation, bending, or fractures)
Tijdsspanne: It will be measured during the surgery up to 6 hours.
It will be used 5-likert scale.
It will be measured during the surgery up to 6 hours.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Bıçakcılar Tıbbi Cihazlar Sanayi ve Ticaret A.Ş.

Onderzoekers

  • Hoofdonderzoeker: Atıf Akçevin, Prof. Dr., Koc University Hospital
  • Studie directeur: Ozan Onur Balkanay, Prof. Dr., İstanbul University-Cerrahpaşa Prof. Dr. Murat Dilmener Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 juli 2026

Primaire voltooiing (Geschat)

1 september 2026

Studie voltooiing (Geschat)

1 oktober 2026

Studieregistratiedata

Eerst ingediend

21 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

1 juni 2026

Eerst geplaatst (Werkelijk)

5 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

1 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • CIP-33003

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren